Play It Safe

The way grants are doled out leads researchers to play it safe -- and that's why there has been little progress in the "war on cancer," writes Gina Kolata in the New York Times. Incremental research is chosen by reviewers because "with too little money to finance most proposals, they are timid about taking chances on ones that might not succeed," Kolata writes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.